Paroxetine treatment improves motor symptoms in patients with multiple system atrophy - PubMed (original) (raw)
Randomized Controlled Trial
Paroxetine treatment improves motor symptoms in patients with multiple system atrophy
Elisabeth Friess et al. Parkinsonism Relat Disord. 2006 Oct.
Abstract
Purpose: In view of the putative role of serotonergic neurotransmission in basal ganglia circuitry we investigated the effects of paroxetine (PXT) as a selective serotonin reuptake inhibitor (SSRI) on the motor performance in n=19 patients clinically diagnosed as MSA using a double-blind placebo-controlled randomized study design. In addition, we assessed the effects on the psychopathological status of the patients.
Results: The short-term add-on treatment with PXT up to 30 mg tid for two weeks resulted in a significant improvement of the motor abilities of the upper limbs and speech when compared to placebo. The treatment with PXT was generally well tolerated. The degree of depressive symptoms was not significantly influenced by PXT or placebo during the observation period.
Conclusions: Previous observations suggest that serotonergic projections may modulate the neuronal excitability of the mesolimbic system and cerebellar system. The observed effects of PXT on motor performance may therefore be due to a direct action of the drug on the motor system. However, these results should be regarded as preliminary, and further research is suggested to evaluate the long-term outcome and clinical relevance of SSRI co-medication in MSA.
Similar articles
- Central effects of lipoic acid associated with paroxetine in mice.
Silva MC, Sampaio LR, de Araújo DP, Araújo PV, Monte AS, Rodrigues FT, Woods DJ, de Sousa FC, Fonteles MM, Vasconcelos SM. Silva MC, et al. Am J Ther. 2014 Mar-Apr;21(2):85-90. doi: 10.1097/MJT.0b013e318235f1a4. Am J Ther. 2014. PMID: 23797756 - Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects.
Loubinoux I, Pariente J, Rascol O, Celsis P, Chollet F. Loubinoux I, et al. Neuropsychologia. 2002;40(11):1815-21. doi: 10.1016/s0028-3932(02)00030-1. Neuropsychologia. 2002. PMID: 12062893 Clinical Trial. - Focus on paroxetine.
Green B. Green B. Curr Med Res Opin. 2003;19(1):13-21. doi: 10.1185/030079902125001353. Curr Med Res Opin. 2003. PMID: 12661775 Review. - Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies.
Stein DJ, Davidson J, Seedat S, Beebe K. Stein DJ, et al. Expert Opin Pharmacother. 2003 Oct;4(10):1829-38. doi: 10.1517/14656566.4.10.1829. Expert Opin Pharmacother. 2003. PMID: 14521492 Review.
Cited by
- Recent Advances in Clinical Trials in Multiple System Atrophy.
Bendetowicz D, Fabbri M, Sirna F, Fernagut PO, Foubert-Samier A, Saulnier T, Le Traon AP, Proust-Lima C, Rascol O, Meissner WG. Bendetowicz D, et al. Curr Neurol Neurosci Rep. 2024 Apr;24(4):95-112. doi: 10.1007/s11910-024-01335-0. Epub 2024 Feb 28. Curr Neurol Neurosci Rep. 2024. PMID: 38416311 Review. - Symptomatic Care in Multiple System Atrophy: State of the Art.
Grossauer A, Sidoroff V, Heim B, Seppi K. Grossauer A, et al. Cerebellum. 2023 Jun;22(3):433-446. doi: 10.1007/s12311-022-01411-6. Epub 2022 May 17. Cerebellum. 2023. PMID: 35581488 Free PMC article. Review. - Nocebo effect in multiple system atrophy: systematic review and meta-analysis of placebo-controlled clinical trials.
Wang ZX, Zhang NN, Zhao HX, Song J. Wang ZX, et al. Neurol Sci. 2022 Feb;43(2):899-905. doi: 10.1007/s10072-021-05758-2. Epub 2022 Jan 1. Neurol Sci. 2022. PMID: 34973075 Free PMC article. Review. - In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons.
Fouka M, Mavroeidi P, Tsaka G, Xilouri M. Fouka M, et al. Front Cell Dev Biol. 2020 Sep 4;8:559791. doi: 10.3389/fcell.2020.559791. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33015057 Free PMC article. Review. - Current Management and Emerging Therapies in Multiple System Atrophy.
Burns MR, McFarland NR. Burns MR, et al. Neurotherapeutics. 2020 Oct;17(4):1582-1602. doi: 10.1007/s13311-020-00890-x. Neurotherapeutics. 2020. PMID: 32767032 Free PMC article. Review.